Early improvements in signs and symptoms predict clinical response to baricitinib in patients with moderate-to-severe atopic dermatitis.
Sign Up to like & getrecommendations! Published in 2023 at "Clinical and experimental dermatology"
DOI: 10.1093/ced/llad129
Abstract: BACKGROUND Early prediction of therapeutic response can optimise treatment strategies in atopic dermatitis (AD). Baricitinib is approved for moderate-to-severe AD in Europe, Japan and other countries. AIM To identify early clinical improvements that reliably predict… read more here.
Keywords: clinical response; baricitinib; itch nrs; moderate severe ... See more keywords